New immune cell therapy takes on Hard-to-Treat myeloma
NCT ID NCT03710421
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This early-phase trial tests a new immune cell therapy called CS1-CAR T cells for people with multiple myeloma that has come back or not responded to treatment. The therapy involves taking a patient's own immune cells, engineering them in a lab to recognize and attack myeloma cells, and infusing them back after chemotherapy. The main goals are to find the safest dose and to watch for side effects in 30 adult participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CS1-CAR T cells (engineered immune cells)
What this could lead to
If successful, this could lead to a new treatment option for multiple myeloma that has stopped responding to other therapies.
What could go wrong
This is an early Phase 1 trial with only 30 participants, so safety and effectiveness are not yet proven. There are risks of serious side effects like cytokine release syndrome and prolonged low white blood cell counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States